Tag Archives: gaucher disease

April, 2018

September, 2017

  • 22 September

    Avrobio Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following on the heels of the Company’s Phase 1 Fabry program …

April, 2017

February, 2017

October, 2015

  • 13 October

    Protalix Sells its Share of its Gaucher Drug to Pfizer for $46 Million

    CARMIEL, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company sold its share in the collaboration agreement for ELELYSOTM to its commercialization partner, Pfizer Inc. Under the initial collaboration agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of ELELYSO on a 60%/40% …

February, 2015